A Phase 2 interventional study of Faricimab and Ranibizumab in Choroidal Neovascularization, sponsored by Hoffmann-La Roche. Completed at 52 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-11-12.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 9th largest by enrollment, is one of 3 that started in 2015, is one of 10 in phase 2, and was the 44th registered.
214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.
Browse Choroidal Neovascularization studies →None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 15 · Phase 3 12 · Phase 4 12
First in 2005; this study’s year is marked. 3 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 273 is above the median of 56 across 160 interventional studies indexed under Choroidal Neovascularization.
Median enrollment 62 across the 45 interventional studies. Of the 44 that completed or were terminated, 23 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 45 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 5 studies filed under Choroidal Neovascularization — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 45 studies testing ranibizumab in Choroidal Neovascularization, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multiple-center, multiple-dose and regimen, randomized, double-masked active comparator-controlled, double-masked, five parallel group, 36-week study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of faricimab (RO6867461) in participants with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).
The study was designed to allow the evaluation of RO6867461 in a treatment-naive population (comparison of Arms A, B, C, and D) and an anti-VEGF-incomplete responder population that met a predefined criterion at Week 12 (comparison between Arms A and E). Only one eye per participant was chosen as the study eye.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
Drug: Ranibizumab
Participants will receive faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.
Drug: Faricimab
Participants will receive faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit will take place at Week 36.
Drug: Faricimab
Participants will receive faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit will take place at Week 36.
Drug: Faricimab · Drug: Sham Procedure
Participants will receive ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit will take place at Week 36.
Drug: Faricimab · Drug: Ranibizumab
Faricimab will be administered as per the regimen specified in the individual arm.
Also known as: RO6867461, RG7716
Ranibizumab will be administered as per the regimen specified in the individual arm.
Also known as: Lucentis
The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in treatment arm D at applicable visits to maintain masking.
Mean Change From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The primary analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
Time frame: Baseline, Week 36
Mean Change From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The primary analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
Time frame: Weeks 12 and 36
Percentage of Participants Gaining Greater Than or Equal to (≥) 15 Letters From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.
Time frame: Baseline, Week 36
Percentage of Participants Gaining ≥15 Letters From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.
Time frame: Weeks 12 and 36
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Treatment-Naive Participants
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.
Time frame: Week 36
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Anti-VEGF Incomplete Responders
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.
Time frame: Week 36
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Treatment-Naive Participants
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.
Time frame: Week 36
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Anti-VEGF Incomplete Responders
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.
Time frame: Week 36
Mean Change From Baseline in Foveal Center Point Thickness at Week 36, as Measured by Spectral Domain Optical Coherence Tomography (SD-OCT), in Treatment-Naive Participants
Foveal center point thickness (FCPT) is defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea. Foveal center point thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
Time frame: Baseline, Week 36
Mean Change From Week 12 in Foveal Center Point Thickness at Week 36, as Measured by SD-OCT, in Anti-VEGF Incomplete Responders
Foveal center point thickness (FCPT) is defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea. Foveal center point thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
Time frame: Weeks 12 and 36
Mean Change From Baseline in Central Subfield Thickness at Week 36, as Measured by SD-OCT, in Treatment-Naive Participants
Central subfield thickness (CST) is defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. Central subfield thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
Time frame: Baseline, Week 36
Mean Change From Week 12 in Central Subfield Thickness at Week 36, as Measured by SD-OCT in Anti-VEGF Incomplete Responders
Central subfield thickness (CST) is defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. Central subfield thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
Time frame: Weeks 12 and 36
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants
The presence of cysts, intraretinal fluid, pigment epithelial detachment, or subretinal fluid, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. Intraretinal fluid was defined as the presence of fluid within the retina. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center.
Time frame: Baseline, Week 36
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders
The presence of cysts, intraretinal fluid, pigment epithelial detachment, or subretinal fluid, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. Intraretinal fluid was defined as the presence of fluid within the retina. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center.
Time frame: Weeks 12 and 36
Mean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by Fundus Fluorescein Angiography (FFA), in Treatment-Naive Participants
The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
Time frame: Baseline, Week 36
Mean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders
The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA).
Time frame: Weeks 12 and 36
Mean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Treatment-Naive Participants
The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
Time frame: Baseline, Week 36
Mean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders
The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA).
Time frame: Weeks 12 and 36
Mean Change From Baseline in Total Area of Leakage at Week 36, as Measured by FFA, in Treatment-Naive Participants
The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
Time frame: Baseline, Week 36
Mean Change From Week 12 in Total Area of Leakage at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders
The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA).
Time frame: Weeks 12 and 36
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants
This safety summary reports the number and percentage of participants who experienced at least one adverse event (AE) during the study. AEs are categorized as any AEs, ocular AEs occurring in the study eye or fellow eye, systemic AEs, serious AEs, AEs related to treatment with study drug, AEs leading to discontinuation (withdrawal) of treatment with study drug, and AEs with fatal outcome. The investigator independently assessed the seriousness and severity for each AE. Severity was graded according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Severity and seriousness are not synonymous; regardless of severity, some AEs may have also met seriousness criteria.
Time frame: From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Number of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye by Highest Intensity, in All Participants
The investigator assessed adverse event severity according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Only the most severe intensity was counted for multiple occurrences of the same adverse event per participant at the preferred term level. Severity and seriousness are not synonymous; regardless of severity, some adverse events may have also met seriousness criteria.
Time frame: From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Number of Participants With at Least One Systemic Adverse Event by Highest Intensity, in All Participants
The investigator assessed adverse event severity according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Only the most severe intensity was counted for multiple occurrences of the same adverse event per participant at the preferred term level. Severity and seriousness are not synonymous; regardless of severity, some adverse events may have also met seriousness criteria.
Time frame: From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Number of Participants With Abnormal Systolic Blood Pressure, in All Participants
Abnormal systolic blood pressure (supine) was defined as any value outside of the standard reference range, from \<70 (low) to \>140 (high) millimetres of mercury (mmHg). Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.
Time frame: Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Number of Participants With Abnormal Diastolic Blood Pressure, in All Participants
Abnormal diastolic blood pressure (supine) was defined as any value outside of the standard reference range, from \<40 (low) to \>90 (high) millimetres of mercury (mmHg). Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.
Time frame: Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Number of Participants With Abnormal Heart Rate, in All Participants
Abnormal heart rate (supine) was defined as any value outside of the standard reference range, from \<40 (low) to \>100 (high) beats per minute. Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.
Time frame: Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Number of Participants With Abnormal Body Temperature, in All Participants
Abnormal body temperature (supine) was defined as any value outside of the standard reference range, from \<36.5 (low) to \>37.5 (high) degrees Celsius. Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.
Time frame: Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants
Clinical laboratory tests for hematology and coagulation parameters were performed and any marked abnormal values (High or Low) were based on Roche's predefined standard reference ranges. Marked laboratory abnormalities are presented according to COG3007 abnormality criteria: Single, Not Last = abnormality detected at a single assessment, but not at the last assessment; Last or Replicated = abnormality detected at the last assessment or replicated at one or more assessments. Not every laboratory abnormality qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Abs. = absolute count; Corp. = corpuscular; Ery. = erythrocyte; INR = International Normalized Ratio
Time frame: Predose at Baseline, Weeks 12 and 36, and at Early Termination and Unscheduled Visits (up to 36 weeks)
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants
Clinical laboratory tests for blood chemistry parameters were performed and any marked abnormal values (High or Low) were based on Roche's predefined standard reference ranges. Marked laboratory abnormalities are presented according to COG3007 abnormality criteria: Single, Not Last = abnormality detected at a single assessment, but not at the last assessment; Last or Replicated = abnormality detected at the last assessment or replicated at one or more assessments. Not every laboratory abnormality qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. GGT = gamma-glutamyltransferase; SGOT/AST = serum glutamic oxaloacetic transaminase / aspartate aminotransferase; SGPT/ALT = serum glutamic pyruvic transaminase / alanine aminotransferase
Time frame: Predose at Baseline, Weeks 12 and 36, and at Early Termination and Unscheduled Visits (up to 36 weeks)
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants
Intraocular pressure is the fluid pressure inside the eye. The method used to measure intraocular pressure (e.g., Goldmann tonometry) for each participant was to be applied consistently by the investigator throughout the study. On the day of dosing, intraocular pressure was monitored at 30 minutes post-treatment administration, and if intraocular pressure was ≥30 mmHg in the study eye, it was reassessed at 1 hour post-treatment administration.
Time frame: Baseline, 0.5 hours postdose on Day 1, predose and 0.5 hours postdose at Weeks 4, 8, 12, 16, 20, 24, 28, and 32, and at Weeks 1, 13, and 36
Change From Baseline in the Number of Participants With Anti-Drug Antibodies to Faricimab at Any Post-Baseline Timepoint
Blood samples were obtained for measurement of anti-faricimab antibodies by a validated enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline, Predose (0 hour) on Days 1, 28, 84, 112, 168, and 252 or early termination (up to 36 weeks)
Mean Plasma Concentration of Faricimab Over Time, in All Participants
Plasma concentrations of faricimab were measured by a specific validated enzyme-linked immunoabsorbent assay (ELISA) only from samples of participants randomized to receive faricimab. Baseline was defined as the last non-missing predose assessment. The lower limit of quantification (LLOQ) for the faricimab assay was 0.800 nanograms per millilitre (ng/mL). Values below the limit of quantification were imputed as LLOQ divided by 2.
Time frame: Predose (on days when treatment was administered) at Baseline and Weeks 4, 12, 13, 16, 24, and 36
Mean Change From Baseline in Free Vascular Endothelial Growth Factor-A (VEGF-A) Plasma Concentrations Over Time, in All Participants
The concentration of free VEGF was determined in plasma samples using an enzyme-linked immunosorbent assay (ELISA) method. The lower limit of quantification (LLOQ) of the assay was 15.6 picograms per millilitre (pg/mL). Plasma free VEGF concentrations below the limit of quantification were imputed as LLOQ divided by 2.
Time frame: Baseline, Weeks 4, 12, 13, 16, 24, and 36
Mean Change From Baseline in Total Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants
Total Ang-2 concentrations were determined in plasma samples using an appropriate assay method. The lower limit of quantification (LLOQ) of the assay was 0.09 nanograms per millilitre (ng/mL). Plasma total Ang-2 concentrations below the limit of quantification were imputed as LLOQ divided by 2.
Time frame: Baseline, Weeks 4, 12, 13, 16, 24, and 36
Mean Change From Baseline in Free Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants
Free Ang-2 concentrations were determined in plasma samples using an appropriate assay method. The lower limit of quantification (LLOQ) of the assay was 0.9 nanograms per millilitre (ng/mL). Plasma free Ang-2 concentrations below the limit of quantification were imputed as LLOQ divided by 2.
Time frame: Baseline, Weeks 4, 12, 13, 16, 24, and 36
| Milestone | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Started | 68 | 46 | 39 | 46 | 64 |
| Received at least one dose of study drug | 67 | 46 | 39 | 46 | 64 |
| Completed | 64 | 40 | 36 | 44 | 58 |
| Not completed | 4 | 6 | 3 | 2 | 6 |
| Withdrew: Adverse event | 1 | 3 | 0 | 0 | 5 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 1 | 3 | 1 | 2 | 0 |
| Withdrew: Physician decision | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The primary analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
| BCVA Letters | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks |
|---|---|---|---|---|
| Mean Change From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants | 7.61 (5.43 to 9.80) | 9.18 (6.54 to 11.83) | 6.02 (3.24 to 8.80) | 6.10 (3.56 to 8.64) |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The primary analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
| BCVA Letters | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|
| Mean Change From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders | 1.72 (-0.69 to 4.13) | 0.04 (-2.27 to 2.35) |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.
| Percentage of Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks |
|---|---|---|---|---|
| Percentage of Participants Gaining Greater Than or Equal to (≥) 15 Letters From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants | 31.0 (24.1 to 38.8) | 36.6 (27.6 to 46.7) | 27.9 (19.6 to 38.0) | 23.7 (16.5 to 32.7) |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.
| Percentage of Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|
| Percentage of Participants Gaining ≥15 Letters From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders | 5.71 (0.69 to 10.74) | 0.00 (0.00 to 0.00) |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.
| Percentage of Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks |
|---|---|---|---|---|
| Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Treatment-Naive Participants | 49.5 (41.6 to 57.4) | 49.0 (39.2 to 58.8) | 39.4 (29.8 to 49.9) | 41.8 (32.8 to 51.4) |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.
| Percentage of Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|
| Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Anti-VEGF Incomplete Responders | 22.86 (13.76 to 31.95) | 16.22 (8.45 to 23.98) |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.
| Percentage of Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks |
|---|---|---|---|---|
| Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Treatment-Naive Participants | 7.7 (4.4 to 13.2) | 8.7 (4.6 to 16.0) | 15.8 (9.6 to 25.0) | 8.8 (4.7 to 15.9) |
Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.
| Percentage of Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|
| Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Anti-VEGF Incomplete Responders | 14.29 (6.71 to 21.87) | 13.51 (6.31 to 20.72) |
Foveal center point thickness (FCPT) is defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea. Foveal center point thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
| micrometres (μm) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks |
|---|---|---|---|---|
| Mean Change From Baseline in Foveal Center Point Thickness at Week 36, as Measured by Spectral Domain Optical Coherence Tomography (SD-OCT), in Treatment-Naive Participants | -194.00 (-207.01 to -181.00) | -181.35 (-196.90 to -165.81) | -193.12 (-209.49 to -176.76) | -161.20 (-176.15 to -146.25) |
Foveal center point thickness (FCPT) is defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea. Foveal center point thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
| micrometres (μm) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|
| Mean Change From Week 12 in Foveal Center Point Thickness at Week 36, as Measured by SD-OCT, in Anti-VEGF Incomplete Responders | -14.5 (-28.7 to -0.2) | -20.8 (-34.5 to -7.1) |
Central subfield thickness (CST) is defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. Central subfield thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
| micrometres (μm) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks |
|---|---|---|---|---|
| Mean Change From Baseline in Central Subfield Thickness at Week 36, as Measured by SD-OCT, in Treatment-Naive Participants | -176.18 (-188.94 to -163.43) | -156.73 (-171.85 to -141.61) | -173.40 (-189.40 to -157.40) | -147.66 (-162.27 to -133.05) |
Central subfield thickness (CST) is defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. Central subfield thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
| micrometres (μm) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|
| Mean Change From Week 12 in Central Subfield Thickness at Week 36, as Measured by SD-OCT in Anti-VEGF Incomplete Responders | -17.00 (-33.12 to -0.88) | -31.42 (-46.83 to -16.02) |
The presence of cysts, intraretinal fluid, pigment epithelial detachment, or subretinal fluid, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. Intraretinal fluid was defined as the presence of fluid within the retina. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center.
| Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks |
|---|---|---|---|---|
| Cysts: Present at Baseline | 52 | 29 | 29 | 38 |
| Cysts: Present at Week 36 | 13 | 7 | 6 | 11 |
| Cysts: Absent at Week 36 | 36 | 18 | 21 | 25 |
| Intraretinal Fluid: Present at Baseline | 67 | 46 | 39 | 45 |
| Intraretinal Fluid: Present at Week 36 | 46 | 27 | 28 | 34 |
| Intraretinal Fluid: Absent at Week 36 | 18 | 13 | 9 | 9 |
| Pigment Epithelial Detachment: Present at Baseline | 58 | 37 | 27 | 36 |
| Pigment Epithelial Detachment: Present at Week 36 | 43 | 25 | 20 | 32 |
| Pigment Epithelial Detachment: Absent at Week 36 | 12 | 6 | 6 | 4 |
| Subretinal Fluid: Present at Baseline | 56 | 41 | 30 | 35 |
| Subretinal Fluid: Present at Week 36 | 11 | 18 | 3 | 8 |
| Subretinal Fluid: Absent at Week 36 | 42 | 18 | 26 | 25 |
The presence of cysts, intraretinal fluid, pigment epithelial detachment, or subretinal fluid, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. Intraretinal fluid was defined as the presence of fluid within the retina. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center.
| Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|
| Cysts: Present at Week 12 | 9 | 11 |
| Cysts: Present at Week 36 | 4 | 5 |
| Cysts: Absent at Week 36 | 5 | 6 |
| Intraretinal Fluid: Present at Week 12 | 28 | 36 |
| Intraretinal Fluid: Present at Week 36 | 19 | 28 |
| Intraretinal Fluid: Absent at Week 36 | 7 | 7 |
| Pigment Epithelial Detachment: Present at Week 12 | 24 | 28 |
| Pigment Epithelial Detachment: Present at Week 36 | 19 | 22 |
| Pigment Epithelial Detachment: Absent at Week 36 | 3 | 5 |
| Subretinal Fluid: Present at Week 12 | 10 | 9 |
| Subretinal Fluid: Present at Week 36 | 3 | 2 |
| Subretinal Fluid: Absent at Week 36 | 5 | 6 |
The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
| millimetres squared (mm^2) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks |
|---|---|---|---|---|
| Mean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by Fundus Fluorescein Angiography (FFA), in Treatment-Naive Participants | -3.41 (-4.34 to -2.49) | -3.81 (-4.93 to -2.70) | -3.19 (-4.29 to -2.08) | -3.31 (-4.31 to -2.30) |
The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA).
| millimetres squared (mm^2) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|
| Mean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders | -0.50 ± 2.37 | -1.37 ± 3.72 |
The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
| millimetres squared (mm^2) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks |
|---|---|---|---|---|
| Mean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Treatment-Naive Participants | -4.18 (-5.09 to -3.27) | -5.14 (-6.24 to -4.04) | -2.96 (-4.09 to -1.82) | -3.83 (-4.84 to -2.82) |
The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA).
| millimetres squared (mm^2) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|
| Mean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders | -1.87 ± 4.05 | -1.88 ± 3.98 |
The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.
| millimetres squared (mm^2) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks |
|---|---|---|---|---|
| Mean Change From Baseline in Total Area of Leakage at Week 36, as Measured by FFA, in Treatment-Naive Participants | -5.15 (-6.10 to -4.20) | -5.94 (-7.10 to -4.77) | -3.71 (-4.88 to -2.53) | -4.66 (-5.70 to -3.61) |
The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA).
| millimetres squared (mm^2) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|
| Mean Change From Week 12 in Total Area of Leakage at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders | -1.87 ± 4.05 | -2.00 ± 3.98 |
This safety summary reports the number and percentage of participants who experienced at least one adverse event (AE) during the study. AEs are categorized as any AEs, ocular AEs occurring in the study eye or fellow eye, systemic AEs, serious AEs, AEs related to treatment with study drug, AEs leading to discontinuation (withdrawal) of treatment with study drug, and AEs with fatal outcome. The investigator independently assessed the seriousness and severity for each AE. Severity was graded according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Severity and seriousness are not synonymous; regardless of severity, some AEs may have also met seriousness criteria.
| Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Any Adverse Event (AE) | 51 | 39 | 31 | 39 | 54 |
| Ocular AE in Either Eye | 39 | 25 | 23 | 29 | 37 |
| Ocular AE in the Study Eye | 28 | 21 | 21 | 27 | 28 |
| Ocular AE in the Fellow Eye | 21 | 16 | 9 | 18 | 20 |
| Serious Ocular AE in the Study Eye | 0 | 3 | 0 | 0 | 2 |
| Ocular AE in Study Eye Leading to Withdrawal | 0 | 1 | 0 | 0 | 4 |
| Systemic AE | 37 | 37 | 23 | 30 | 43 |
| Serious Systemic AE | 9 | 7 | 7 | 4 | 6 |
| Systemic AE Leading to Withdrawal | 1 | 2 | 0 | 0 | 2 |
| AE with Fatal Outcome | 0 | 0 | 0 | 0 | 1 |
| Any Serious AE | 9 | 11 | 7 | 5 | 8 |
| Any Related Serious AE | 0 | 1 | 0 | 0 | 0 |
| Any Related AE | 3 | 4 | 3 | 3 | 0 |
| Related Ocular AE in the Study Eye | 3 | 4 | 3 | 3 | 0 |
| Related Systemic AE | 0 | 0 | 0 | 0 | 0 |
The investigator assessed adverse event severity according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Only the most severe intensity was counted for multiple occurrences of the same adverse event per participant at the preferred term level. Severity and seriousness are not synonymous; regardless of severity, some adverse events may have also met seriousness criteria.
| Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Study Eye - Adverse Event (AE) of Any Grade | 28 | 21 | 21 | 27 | 28 |
| Study Eye - Mild AE | 27 | 19 | 20 | 25 | 24 |
| Study Eye - Moderate AE | 4 | 2 | 3 | 6 | 8 |
| Study Eye - Severe AE | 0 | 3 | 0 | 0 | 2 |
| Fellow Eye - AE of Any Grade | 21 | 16 | 9 | 18 | 20 |
| Fellow Eye - Mild AE | 15 | 14 | 7 | 17 | 17 |
| Fellow Eye - Moderate AE | 5 | 1 | 4 | 1 | 2 |
| Fellow Eye - Severe AE | 1 | 1 | 0 | 0 | 2 |
The investigator assessed adverse event severity according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Only the most severe intensity was counted for multiple occurrences of the same adverse event per participant at the preferred term level. Severity and seriousness are not synonymous; regardless of severity, some adverse events may have also met seriousness criteria.
| Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Any Grade | 37 | 37 | 23 | 30 | 43 |
| Mild | 30 | 27 | 17 | 23 | 28 |
| Moderate | 16 | 18 | 14 | 13 | 26 |
| Severe | 7 | 2 | 5 | 4 | 4 |
Abnormal systolic blood pressure (supine) was defined as any value outside of the standard reference range, from \<70 (low) to \>140 (high) millimetres of mercury (mmHg). Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.
| Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Low | 0 | 0 | 0 | 0 | 0 |
| High | 20 | 13 | 13 | 23 | 25 |
Abnormal diastolic blood pressure (supine) was defined as any value outside of the standard reference range, from \<40 (low) to \>90 (high) millimetres of mercury (mmHg). Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.
| Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Low | 0 | 0 | 0 | 0 | 0 |
| High | 15 | 9 | 8 | 10 | 9 |
Abnormal heart rate (supine) was defined as any value outside of the standard reference range, from \<40 (low) to \>100 (high) beats per minute. Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.
| Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Low | 1 | 0 | 1 | 0 | 0 |
| High | 1 | 0 | 1 | 1 | 1 |
Abnormal body temperature (supine) was defined as any value outside of the standard reference range, from \<36.5 (low) to \>37.5 (high) degrees Celsius. Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.
| Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Low | 28 | 19 | 14 | 25 | 29 |
| High | 4 | 1 | 1 | 2 | 6 |
Clinical laboratory tests for hematology and coagulation parameters were performed and any marked abnormal values (High or Low) were based on Roche's predefined standard reference ranges. Marked laboratory abnormalities are presented according to COG3007 abnormality criteria: Single, Not Last = abnormality detected at a single assessment, but not at the last assessment; Last or Replicated = abnormality detected at the last assessment or replicated at one or more assessments. Not every laboratory abnormality qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Abs. = absolute count; Corp. = corpuscular; Ery. = erythrocyte; INR = International Normalized Ratio
| Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Basophils, Abs., High - Any Abnormality | 1 | 0 | 0 | 0 | 0 |
| Basophils, Abs., High - Single, Not Last | 1 | 0 | 0 | 0 | 0 |
| Basophils, Abs., High - Last or Replicated | 0 | 0 | 0 | 0 | 0 |
| Eosinophils, Abs., High - Any Abnormality | 0 | 0 | 0 | 3 | 0 |
| Eosinophils, Abs., High - Single, Not Last | 0 | 0 | 0 | 1 | 0 |
| Eosinophils, Abs., High - Last or Replicated | 0 | 0 | 0 | 2 | 0 |
| Ery. Mean Corp. Volume, Low - Any Abnormality | 0 | 0 | 0 | 1 | 0 |
| Ery. Mean Corp. Volume, Low - Single, Not Last | 0 | 0 | 0 | 1 | 0 |
| Ery. Mean Corp. Volume, Low - Last or Replicated | 0 | 0 | 0 | 0 | 0 |
| Hematocrit, Low - Any Abnormality | 1 | 0 | 1 | 0 | 0 |
| Hematocrit, Low - Single, Not Last | 1 | 0 | 1 | 0 | 0 |
| Hematocrit, Low - Last or Replicated | 0 | 0 | 0 | 0 | 0 |
| Hemoglobin, Low - Any Abnormality | 3 | 0 | 1 | 2 | 2 |
| Hemoglobin, Low - Single, Not Last | 2 | 0 | 0 | 0 | 1 |
| Hemoglobin, Low - Last or Replicated | 1 | 0 | 1 | 2 | 1 |
| Lymphocytes, Abs., Low - Any Abnormality | 0 | 1 | 1 | 2 | 1 |
| Lymphocytes, Abs., Low - Single, Not Last | 0 | 1 | 1 | 0 | 1 |
| Lymphocytes, Abs., Low - Last or Replicated | 0 | 0 | 0 | 2 | 0 |
| Lymphocytes, Abs., High - Any Abnormality | 0 | 0 | 0 | 1 | 0 |
| Lymphocytes, Abs., High - Single, Not Last | 0 | 0 | 0 | 0 | 0 |
| Lymphocytes, Abs., High - Last or Replicated | 0 | 0 | 0 | 1 | 0 |
| Lymphocytes, Pct., Low - Any Abnormality | 0 | 1 | 0 | 0 | 0 |
| Lymphocytes, Pct., Low - Single, Not Last | 0 | 1 | 0 | 0 | 0 |
| Lymphocytes, Pct., Low - Last or Replicated | 0 | 0 | 0 | 0 | 0 |
| Neutrophils, Total, Abs., Low - Any Abnormality | 0 | 1 | 2 | 3 | 1 |
| Neutrophils, Total, Abs., Low - Single, Not Last | 0 | 1 | 1 | 1 | 0 |
| Neutrophils, Total, Abs., Low - Last or Replicated | 0 | 0 | 1 | 2 | 1 |
| Neutrophils, Total, Abs., High - Any Abnormality | 2 | 1 | 0 | 0 | 2 |
| Neutrophils, Total, Abs., High - Single, Not Last | 1 | 0 | 0 | 0 | 2 |
| Neutrophils, Total, Abs., High -Last or Replicated | 1 | 1 | 0 | 0 | 0 |
| Platelets, Low - Any Abnormality | 0 | 0 | 0 | 2 | 1 |
| Platelets, Low - Single, Not Last | 0 | 0 | 0 | 1 | 0 |
| Platelets, Low - Last or Replicated | 0 | 0 | 0 | 1 | 1 |
| White Blood Cell Count, Low - Any Abnormality | 0 | 0 | 0 | 1 | 1 |
| White Blood Cell Count, Low - Single, Not Last | 0 | 0 | 0 | 1 | 1 |
| White Blood Cell Count, Low - Last or Replicated | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Count, High - Any Abnormality | 0 | 0 | 0 | 1 | 0 |
| White Blood Cell Count, High - Single, Not Last | 0 | 0 | 0 | 0 | 0 |
| White Blood Cell Count, High - Last or Replicated | 0 | 0 | 0 | 1 | 0 |
| INR, High - Any Abnormality | 0 | 0 | 0 | 1 | 0 |
| INR, High - Single, Not Last | 0 | 0 | 0 | 0 | 0 |
| INR, High - Last or Replicated | 0 | 0 | 0 | 1 | 0 |
Clinical laboratory tests for blood chemistry parameters were performed and any marked abnormal values (High or Low) were based on Roche's predefined standard reference ranges. Marked laboratory abnormalities are presented according to COG3007 abnormality criteria: Single, Not Last = abnormality detected at a single assessment, but not at the last assessment; Last or Replicated = abnormality detected at the last assessment or replicated at one or more assessments. Not every laboratory abnormality qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. GGT = gamma-glutamyltransferase; SGOT/AST = serum glutamic oxaloacetic transaminase / aspartate aminotransferase; SGPT/ALT = serum glutamic pyruvic transaminase / alanine aminotransferase
| Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Alkaline Phosphatase, High - Any Abnormality | 0 | 0 | 1 | 0 | 0 |
| Alkaline Phosphatase, High - Single, Not Last | 0 | 0 | 1 | 0 | 0 |
| Alkaline Phosphatase, High - Last or Replicated | 0 | 0 | 0 | 0 | 0 |
| Bicarbonate (CO2), Low - Any Abnormality | 1 | 1 | 0 | 1 | 1 |
| Bicarbonate (CO2), Low - Single, Not Last | 0 | 0 | 0 | 1 | 0 |
| Bicarbonate (CO2), Low - Last or Replicated | 1 | 1 | 0 | 0 | 1 |
| Bicarbonate (CO2), High - Any Abnormality | 5 | 3 | 1 | 3 | 4 |
| Bicarbonate (CO2), High - Single, Not Last | 3 | 0 | 1 | 0 | 2 |
| Bicarbonate (CO2), High - Last or Replicated | 2 | 3 | 0 | 3 | 2 |
| Calcium, Low - Any Abnormality | 0 | 1 | 0 | 0 | 0 |
| Calcium, Low - Single, Not Last | 0 | 0 | 0 | 0 | 0 |
| Calcium, Low - Last or Replicated | 0 | 1 | 0 | 0 | 0 |
| Calcium, High - Any Abnormality | 0 | 0 | 0 | 0 | 1 |
| Calcium, High - Single, Not Last | 0 | 0 | 0 | 0 | 1 |
| Calcium, High - Last or Replicated | 0 | 0 | 0 | 0 | 0 |
| Chloride, Low - Any Abnormality | 1 | 1 | 0 | 0 | 2 |
| Chloride, Low - Single, Not Last | 1 | 1 | 0 | 0 | 0 |
| Chloride, Low - Last or Replicated | 0 | 0 | 0 | 0 | 2 |
| Creatine Kinase, High - Any Abnormality | 2 | 0 | 1 | 3 | 2 |
| Creatine Kinase, High - Single, Not Last | 0 | 0 | 0 | 1 | 1 |
| Creatine Kinase, High - Last or Replicated | 2 | 0 | 1 | 2 | 1 |
| Creatinine, High - Any Abnormality | 0 | 1 | 0 | 0 | 0 |
| Creatinine, High - Single, Not Last | 0 | 1 | 0 | 0 | 0 |
| Creatinine, High - Last or Replicated | 0 | 0 | 0 | 0 | 0 |
| GGT, High - Any Abnormality | 0 | 0 | 0 | 1 | 1 |
| GGT, High - Single, Not Last | 0 | 0 | 0 | 0 | 0 |
| GGT, High - Last or Replicated | 0 | 0 | 0 | 1 | 1 |
| Phosphorus, Low - Any Abnormality | 0 | 1 | 1 | 0 | 1 |
| Phosphorus, Low - Single, Not Last | 0 | 1 | 0 | 0 | 0 |
| Phosphorus, Low - Last or Replicated | 0 | 0 | 1 | 0 | 1 |
| Phosphorus, High - Any Abnormality | 2 | 3 | 2 | 1 | 5 |
| Phosphorus, High - Single, Not Last | 1 | 1 | 1 | 1 | 3 |
| Phosphorus, High - Last or Replicated | 1 | 2 | 1 | 0 | 2 |
| Potassium, High - Any Abnormality | 2 | 1 | 0 | 0 | 1 |
| Potassium, High - Single, Not Last | 1 | 0 | 0 | 0 | 0 |
| Potassium, High - Last or Replicated | 1 | 1 | 0 | 0 | 1 |
| Protein, Total, High - Any Abnormality | 0 | 1 | 0 | 0 | 0 |
| Protein, Total, High - Single, Not Last | 0 | 1 | 0 | 0 | 0 |
| Protein, Total, High - Last or Replicated | 0 | 0 | 0 | 0 | 0 |
| SGOT/AST, High - Any Abnormality | 0 | 0 | 1 | 0 | 1 |
| SGOT/AST, High - Single, Not Last | 0 | 0 | 1 | 0 | 1 |
| SGOT/AST, High - Last or Replicated | 0 | 0 | 0 | 0 | 0 |
| SGPT/ALT, High - Any Abnormality | 1 | 0 | 1 | 0 | 1 |
| SGPT/ALT, High - Single, Not Last | 0 | 0 | 1 | 0 | 1 |
| SGPT/ALT, High - Last or Replicated | 1 | 0 | 0 | 0 | 0 |
Intraocular pressure is the fluid pressure inside the eye. The method used to measure intraocular pressure (e.g., Goldmann tonometry) for each participant was to be applied consistently by the investigator throughout the study. On the day of dosing, intraocular pressure was monitored at 30 minutes post-treatment administration, and if intraocular pressure was ≥30 mmHg in the study eye, it was reassessed at 1 hour post-treatment administration.
| millimetres of mercury (mmHg) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Baseline (BL): Absolute Value | 15.07 ± 3.38 | 14.74 ± 3.08 | 14.69 ± 3.85 | 14.98 ± 2.91 | 14.27 ± 2.80 |
| Change from BL at Day 1 (0.5 hr) | 1.90 ± 4.80 | 2.04 ± 5.32 | 1.59 ± 4.30 | 2.37 ± 4.22 | 3.52 ± 4.79 |
| Change from BL at Week 1 | -0.89 ± 3.52 | -0.98 ± 3.47 | -0.62 ± 3.35 | -1.96 ± 2.98 | 0.11 ± 2.36 |
| Change from BL at Week 4 (Predose) | -0.27 ± 3.16 | -1.40 ± 2.61 | -1.18 ± 3.85 | -0.87 ± 2.99 | 0.59 ± 2.49 |
| Change from BL at Week 4 (0.5 hr) | 2.88 ± 4.45 | 2.70 ± 3.56 | 2.05 ± 4.26 | 1.51 ± 3.96 | 3.59 ± 4.39 |
| Change from BL at Week 8 (Predose) | -0.56 ± 3.85 | -0.32 ± 3.13 | -0.69 ± 3.07 | -0.87 ± 2.75 | 0.10 ± 2.64 |
| Change from BL at Week 8 (0.5 hr) | 2.70 ± 4.21 | 2.59 ± 4.64 | 2.37 ± 5.15 | 1.93 ± 3.91 | 3.93 ± 4.52 |
| Change from BL at Week 12 (Predose) | -0.17 ± 3.49 | -0.02 ± 2.88 | -0.82 ± 3.37 | 0.13 ± 2.94 | 0.45 ± 2.45 |
| Change from BL at Week 12 (0.5 hr) | 3.08 ± 4.01 | 2.43 ± 3.41 | 2.59 ± 3.95 | 2.11 ± 4.04 | 4.34 ± 5.25 |
| Change from BL at Week 13 | -0.77 ± 3.27 | -0.68 ± 3.12 | -0.71 ± 4.02 | -1.09 ± 2.70 | -0.65 ± 2.75 |
| Change from BL at Week 16 (Predose) | -0.41 ± 3.39 | 0.02 ± 3.10 | -0.77 ± 3.11 | -1.00 ± 2.56 | -0.36 ± 2.83 |
| Change from BL at Week 16 (0.5 hr) | 1.64 ± 4.62 | 1.95 ± 5.35 | 1.67 ± 3.92 | -0.30 ± 3.98 | 3.12 ± 5.27 |
| Change from BL at Week 20 (Predose) | -0.16 ± 3.02 | -1.00 ± 2.73 | 0.08 ± 3.61 | -0.44 ± 3.18 | -0.17 ± 2.71 |
| Change from BL at Week 20 (0.5 hr) | 2.80 ± 4.81 | 1.74 ± 4.85 | 1.82 ± 5.37 | 0.68 ± 5.45 | 2.62 ± 4.54 |
| Change from BL at Week 24 (Predose) | 0.00 ± 3.29 | -0.33 ± 3.30 | 0.26 ± 2.77 | -0.61 ± 2.73 | 0.14 ± 2.73 |
| Change from BL at Week 24 (0.5 hr) | 3.23 ± 3.91 | 3.26 ± 4.04 | 4.11 ± 3.51 | 0.91 ± 3.66 | 4.17 ± 4.28 |
| Change from BL at Week 28 (Predose) | -0.02 ± 2.80 | 0.00 ± 4.30 | -1.00 ± 2.91 | -0.38 ± 2.74 | -0.19 ± 2.89 |
| Change from BL at Week 28 (0.5 hr) | 3.16 ± 4.28 | 2.90 ± 4.13 | 1.74 ± 4.80 | 2.53 ± 3.60 | 3.86 ± 4.49 |
| Change from BL at Week 32 (Predose) | -0.73 ± 3.72 | -0.23 ± 3.63 | -0.41 ± 3.07 | -0.80 ± 2.92 | -0.67 ± 3.06 |
| Change from BL at Week 32 (0.5 hr) | 1.81 ± 5.10 | 3.87 ± 5.58 | 1.63 ± 5.47 | -0.98 ± 4.38 | 2.37 ± 4.97 |
| Change from BL at Week 36 | 0.00 ± 3.30 | 0.25 ± 3.68 | -0.65 ± 3.85 | -0.20 ± 3.55 | -0.16 ± 3.18 |
Blood samples were obtained for measurement of anti-faricimab antibodies by a validated enzyme-linked immunosorbent assay (ELISA).
| Participants | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| ADA Negative to Missing | — | 1 | 0 | 0 | 0 |
| ADA Negative to ADA Negative | — | 41 | 35 | 36 | 54 |
| ADA Negative to ADA Positive | — | 3 | 3 | 9 | 6 |
| ADA Positive to Missing | — | 0 | 0 | 0 | 0 |
| ADA Positive to ADA Negative | — | 1 | 0 | 0 | 0 |
| ADA Positive to ADA Positive | — | 0 | 0 | 1 | 3 |
Plasma concentrations of faricimab were measured by a specific validated enzyme-linked immunoabsorbent assay (ELISA) only from samples of participants randomized to receive faricimab. Baseline was defined as the last non-missing predose assessment. The lower limit of quantification (LLOQ) for the faricimab assay was 0.800 nanograms per millilitre (ng/mL). Values below the limit of quantification were imputed as LLOQ divided by 2.
| nanograms per millilitre (ng/mL) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Baseline | — | 0.40 ± 0.00 | 0.40 ± 0.00 | 0.40 ± 0.00 | 0.47 ± 0.59 |
| Week 4 | — | 8.83 ± 5.85 | 31.06 ± 18.47 | 36.58 ± 19.78 | — |
| Week 12 | — | 18.68 ± 24.38 | 57.92 ± 57.65 | 57.94 ± 73.91 | 45.29 ± 105.64 |
| Week 13 | — | 43.32 ± 31.98 | 184.38 ± 102.01 | 178.25 ± 119.98 | 160.52 ± 124.73 |
| Week 16 | — | 9.52 ± 7.41 | 46.99 ± 35.19 | 43.54 ± 39.05 | 44.71 ± 50.55 |
| Week 24 | — | 9.07 ± 7.39 | 35.30 ± 22.03 | 31.19 ± 24.13 | 37.80 ± 27.75 |
| Week 36 | — | 10.65 ± 8.47 | 36.43 ± 30.80 | 4.69 ± 7.24 | 36.06 ± 26.93 |
The concentration of free VEGF was determined in plasma samples using an enzyme-linked immunosorbent assay (ELISA) method. The lower limit of quantification (LLOQ) of the assay was 15.6 picograms per millilitre (pg/mL). Plasma free VEGF concentrations below the limit of quantification were imputed as LLOQ divided by 2.
| picograms per millilitre (pg/mL) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Baseline (BL) - Value at Visit | 15.25 ± 10.60 | 16.83 ± 12.08 | 24.63 ± 31.47 | 16.53 ± 9.73 | 22.60 ± 27.79 |
| Change from BL at Week 4 | 0.52 ± 12.20 | 3.94 ± 33.25 | -9.26 ± 27.76 | -0.62 ± 15.67 | 3.75 ± 53.99 |
| Change from BL at Week 12 | 1.52 ± 19.45 | -0.46 ± 13.30 | -8.58 ± 20.73 | -4.70 ± 11.79 | -3.24 ± 27.79 |
| Change from BL at Week 13 | 2.62 ± 21.69 | 5.47 ± 52.19 | -14.10 ± 33.55 | -7.36 ± 10.67 | -15.14 ± 33.85 |
| Change from BL at Week 16 | 12.12 ± 67.43 | -3.28 ± 10.61 | -9.86 ± 33.05 | -6.28 ± 10.84 | -5.34 ± 32.90 |
| Change from BL at Week 24 | -0.67 ± 10.45 | 10.35 ± 50.09 | -12.57 ± 31.86 | -5.20 ± 10.07 | -7.19 ± 31.54 |
| Change from BL at Week 36 | 1.91 ± 28.59 | -0.79 ± 11.86 | -12.16 ± 32.48 | -1.34 ± 13.69 | -8.17 ± 29.73 |
Total Ang-2 concentrations were determined in plasma samples using an appropriate assay method. The lower limit of quantification (LLOQ) of the assay was 0.09 nanograms per millilitre (ng/mL). Plasma total Ang-2 concentrations below the limit of quantification were imputed as LLOQ divided by 2.
| nanograms per millilitre (ng/mL) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Baseline (BL) - Value at Visit | 2.14 ± 1.38 | 1.81 ± 0.67 | 1.86 ± 1.12 | 1.80 ± 0.71 | 1.92 ± 0.95 |
| Change from BL at Week 4 | 0.03 ± 0.48 | 0.09 ± 0.39 | 0.09 ± 0.27 | 0.20 ± 0.49 | -0.03 ± 0.38 |
| Change from BL at Week 12 | 0.10 ± 0.89 | 0.14 ± 0.37 | 0.22 ± 0.48 | 0.19 ± 0.50 | -0.11 ± 0.49 |
| Change from BL at Week 13 | 0.18 ± 0.91 | 0.23 ± 0.35 | 1.05 ± 1.15 | 0.87 ± 0.76 | 0.81 ± 0.98 |
| Change from BL at Week 16 | 0.01 ± 0.62 | 0.04 ± 0.71 | 0.24 ± 0.47 | 0.22 ± 0.61 | -0.01 ± 0.52 |
| Change from BL at Week 24 | 0.00 ± 0.68 | 0.11 ± 0.77 | 0.21 ± 0.52 | 0.24 ± 0.57 | 0.04 ± 0.44 |
| Change from BL at Week 36 | 0.08 ± 0.42 | 0.05 ± 0.42 | 0.25 ± 0.39 | 0.33 ± 0.89 | 0.05 ± 0.56 |
Free Ang-2 concentrations were determined in plasma samples using an appropriate assay method. The lower limit of quantification (LLOQ) of the assay was 0.9 nanograms per millilitre (ng/mL). Plasma free Ang-2 concentrations below the limit of quantification were imputed as LLOQ divided by 2.
| nanograms per millilitre (ng/mL) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Baseline (BL) - Value at Visit | 2.19 ± 1.38 | 1.81 ± 0.73 | 1.88 ± 0.98 | 1.73 ± 0.75 | 1.95 ± 1.12 |
| Change from BL at Week 4 | 0.00 ± 0.57 | 0.14 ± 0.37 | -0.05 ± 0.46 | 0.15 ± 0.62 | -0.07 ± 0.55 |
| Change from BL at Week 12 | 0.23 ± 1.12 | 0.20 ± 0.57 | 0.12 ± 0.52 | 0.21 ± 0.75 | -0.01 ± 0.59 |
| Change from BL at Week 13 | 0.03 ± 0.92 | 0.23 ± 0.69 | 0.81 ± 1.11 | 0.55 ± 0.75 | 0.32 ± 0.93 |
| Change from BL at Week 16 | 0.06 ± 0.77 | 0.17 ± 0.95 | 0.15 ± 0.62 | 0.22 ± 0.67 | -0.11 ± 0.65 |
| Change from BL at Week 24 | 0.18 ± 0.90 | 0.20 ± 0.93 | 0.25 ± 0.49 | 0.39 ± 0.58 | 0.13 ± 0.59 |
| Change from BL at Week 36 | 0.16 ± 0.74 | 0.25 ± 0.65 | 0.28 ± 0.63 | 0.51 ± 1.30 | 0.06 ± 0.66 |
Collected over From Baseline until 28 days after the last dose of study treatment (up to 36 weeks). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | 0/67 (0%) | 9/67 (13.4%) | 39/67 (58.2%) |
| Arm B: Faricimab, 1.5 mg Q4W | 0/46 (0%) | 11/46 (23.9%) | 31/46 (67.4%) |
| Arm C: Faricimab, 6 mg Q4W | 0/39 (0%) | 7/39 (17.9%) | 24/39 (61.5%) |
| Arm D: Faricimab, 6 mg Every 4-8 Weeks | 0/46 (0%) | 5/46 (10.9%) | 32/46 (69.6%) |
| Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W | 1/64 (1.6%) | 8/64 (12.5%) | 40/64 (62.5%) |
| Event | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/67 | 0/46 | 1/39 | 0/46 | 0/64 |
| Atrial fibrillationCardiac disorders | 0/67 | 0/46 | 1/39 | 1/46 | 0/64 |
| Chest painGeneral disorders | 0/67 | 0/46 | 1/39 | 0/46 | 0/64 |
| Arteriogram coronaryInvestigations | 0/67 | 0/46 | 1/39 | 0/46 | 0/64 |
| NephrolithiasisRenal and urinary disorders | 0/67 | 0/46 | 1/39 | 0/46 | 0/64 |
| Postmenopausal haemorrhageReproductive system and breast disorders | 0/67 | 0/46 | 1/39 | 0/46 | 0/64 |
| HypertensionVascular disorders | 0/67 | 0/46 | 1/39 | 0/46 | 0/64 |
| ShockVascular disorders | 0/67 | 0/46 | 1/39 | 0/46 | 0/64 |
| Atrial flutterCardiac disorders | 0/67 | 0/46 | 0/39 | 1/46 | 0/64 |
| Keratic PrecipitatesEye disorders | 0/67 | 1/46 | 0/39 | 0/46 | 0/64 |
| Event | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W |
|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 6/67 | 11/46 | 2/39 | 0/46 | 3/64 |
| Conjunctival haemorrhageEye disorders | 14/67 | 4/46 | 6/39 | 6/46 | 6/64 |
| NasopharyngitisInfections and infestations | 9/67 | 4/46 | 1/39 | 1/46 | 5/64 |
| Eye painEye disorders | 2/67 | 4/46 | 2/39 | 5/46 | 3/64 |
| Vitreous detachmentEye disorders | 3/67 | 5/46 | 3/39 | 5/46 | 4/64 |
| Eye irritationEye disorders | 0/67 | 1/46 | 4/39 | 4/46 | 1/64 |
| Vitreous floatersEye disorders | 2/67 | 3/46 | 4/39 | 3/46 | 1/64 |
| Neovascular age-related macular degenerationEye disorders | 6/67 | 4/46 | 3/39 | 2/46 | 5/64 |
| Punctate keratitisEye disorders | 0/67 | 0/46 | 0/39 | 0/46 | 5/64 |
| Posterior capsule opacificationEye disorders | 2/67 | 1/46 | 3/39 | 0/46 | 1/64 |
| Age, Continuous(Years) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W | Total |
|---|---|---|---|---|---|---|
| Mean | 76.4 ± 8.9 | 78.2 ± 8.9 | 78.0 ± 9.1 | 80.0 ± 8.0 | 79.2 ± 8.3 | 78.3 ± 8.7 |
| Sex: Female, Male(Participants) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W | Total |
|---|---|---|---|---|---|---|
| Female | 39 | 32 | 27 | 34 | 40 | 172 |
| Male | 29 | 14 | 12 | 12 | 24 | 91 |
| Ethnicity (NIH/OMB)(Participants) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 0 | 4 | 2 | 13 |
| Not Hispanic or Latino | 64 | 43 | 38 | 42 | 61 | 248 |
| Unknown or Not Reported | 0 | 0 | 1 | 0 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 1 | 0 | 1 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 | 0 | 0 | 1 |
| White | 66 | 45 | 39 | 44 | 64 | 258 |
| More than one race | 1 | 0 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 0 | 1 | 0 | 1 | 0 | 2 |
| Best-Corrected Visual Acuity (BCVA) Letter Score in the Study Eye at Baseline(BCVA Letters) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W | Total |
|---|---|---|---|---|---|---|
| Mean | 55.2 ± 12.7 | 56.7 ± 11.1 | 56.2 ± 12.2 | 56.3 ± 11.5 | 55.7 ± 11.6 | 55.9 ± 11.9 |
| Best-Corrected Visual Acuity (BCVA) Letter Score Category in the Study Eye at Baseline(Participants) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W | Total |
|---|---|---|---|---|---|---|
| BCVA Letter Score ≤54 | 22 | 20 | 15 | 21 | 26 | 104 |
| BCVA Letter Score >54 | 45 | 26 | 24 | 25 | 38 | 158 |
| Assessment Missing | 1 | 0 | 0 | 0 | 0 | 1 |
| Choroidal Neovascularization (CNV) Lesion Type in the Study Eye at Baseline(Participants) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W | Total |
|---|---|---|---|---|---|---|
| Classic & Occult CNV | 26 | 19 | 12 | 20 | 21 | 98 |
| Classic CNV | 8 | 6 | 7 | 6 | 10 | 37 |
| Occult CNV | 33 | 20 | 20 | 19 | 33 | 125 |
| Assessment Missing | 1 | 1 | 0 | 1 | 0 | 3 |
| Presence or Absence of Retinal Angiomatous Proliferation (RAP) in the Study Eye at Baseline(Participants) | Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) | Arm B: Faricimab, 1.5 mg Q4W | Arm C: Faricimab, 6 mg Q4W | Arm D: Faricimab, 6 mg Every 4-8 Weeks | Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W | Total |
|---|---|---|---|---|---|---|
| RAP Absent | 44 | 30 | 29 | 29 | 47 | 179 |
| RAP Present | 22 | 14 | 9 | 14 | 16 | 75 |
| Assessment Missing | 2 | 2 | 1 | 3 | 1 | 9 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2015 to primary completion in Sep 2017, 25 months.
Results were first posted in Oct 2020, 3 years after primary completion. A results delay was requested in Sep 2018.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Faricimab · Ranibizumab
Choroidal Neovascularization →